Genotoxicity assessment is a crucial aspect of the non-clinical safety evaluation of antipsychotic drugs. It is closely linked to other studies, particularly carcinogenicity and reproductive toxicity, and is a key element in the process of potential antipsychotic drugs entering clinical trials and reaching the market. Ace Therapeutics offers comprehensive genotoxicity assessment services for our clients, aiming to reveal the potential effects of drug molecules on genetic material and ensure the safety of potential antipsychotics.

Overview of Genotoxicity Assessment Services for Antipsychotics

Ace Therapeutics employs cutting-edge molecular biology techniques, in vitro cellular models, and animal models to assist clients in evaluating the potential genomic impact of antipsychotic drug candidates. Our toxicity assessment services include a range of validated tests, including mutation assays, chromosomal aberration assays, micronucleus assays, DNA damage assays, and more. Our advanced technology and high-quality services provide accurate and reliable genotoxicological data, which is essential for scientific support in drug development, regulatory requirements, and clinical applications.

Our Genotoxicity Testing Services

• Genetic mutation test

We use in vitro cultured mammalian cell lines or animal models to test whether antipsychotic candidates cause genetic mutations. This can be done through molecular biology techniques such as PCR, gene sequencing, etc. to identify mutations in DNA sequences to assess the potential safety risk of a drug to the genome.

• Chromosome aberration test

We utilize cytogenetic methods to detect the presence of chromosomal aberrations. This allows a comprehensive assessment of the teratogenicity of antipsychotic candidates by examining the number, structure and arrangement of chromosomes for changes through microscopic observation, fluorescence in situ hybridization and other techniques.

• Micronucleus test

We offer a flow cytometry-based high-throughput in vitro micronucleus test for genotoxicity screening. In this test, we provide information on chromosomal damage in cultured or primary cells by detecting the formation of small membrane-bound DNA fragments (micronuclei) in the cytoplasm of interphase cells.

• DNA damage test

We used gel electrophoresis, immunostaining, and real-time fluorescence quantitative PCR to evaluate the possible DNA damage caused by potential antipsychotic drugs. Evaluation metrics included DNA breaks, DNA repair capacity, and DNA damage-related gene expression.

Advantages of Ace Therapeutics

• Specialized testing team provides customized genotoxicity assessment solutions.
• Multi-functional laboratories are equipped with highly sensitive detection technologies to ensure the authenticity and reliability of test results.
• Shorter testing cycle and competitive pricing.

Ace Therapeutics is committed to providing one-stop services for genotoxicity evaluation services to accelerate your antipsychotic drug development process. If you are interested in our services or require further information, please contact us.